Coronavirus disease 2019 (COVID-19) increases the risk of venous thromboembolism, requiring monitoring of low molecular weight heparin (LMWH) via a time-consuming, costly and often unavailable test – anti-factor Xa (anti-Xa). Here, TNXA is linked to venous thromboembolism.